Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

XXX - Atezolizumab + Clostridium butyricum CBM588 vs Clostridium butyricum CBM588 + Nivolumab vs Clostridium butyricum CBM588 + Pembrolizumab vs Nivolumab vs Atezolizumab vs Pembrolizumab & Non-small-cell lung cancer (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background:

Dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB). The Clostridium butyricum CBM588 strain is a probiotic therapy used to improve symptoms related to antibiotic-induced dysbiosis in Japan (1)

Study overview:

XXX - Atezolizumab + Clostridium butyricum CBM588 vs Clostridium butyricum CBM588 + Nivolumab vs Clostridium butyricum CBM588 + Pembrolizumab vs Nivolumab vs Atezolizumab vs Pembrolizumab & Non-small-cell lung cancer (NSCLC) is a retrospective trial evaluating [Atezolizumab + Clostridium butyricum CBM588](brain://3kr0moKwUUmqzMBYI7yaxQ/AtezolizumabClostridium…

References (Sources)

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
Tomita et al. 2020 Cancer Immunology Research 8: 1236

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!